Evidence map›Paper›PMID 37504332›Full record

ArticleCurrent oncology (Toronto, Ont.)2023

Clinical Outcomes in a Large Canadian Centralized CLL Clinic Based on Treatment and Molecular Factors over a Decade.

Jiayu Yang, Lin Yang, Bryan Tordon, Oliver Bucher, Zoann Nugent, Ivan Landego, Nicole Bourrier, Kelsey Uminski, Kevin Brown, Mandy Squires and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 2 institutions in 1 country.

Jiayu YangDepartment of Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3E 3P4, Canada.
Lin YangDepartment of Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3E 3P4, Canada.
Bryan TordonDepartment of Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3E 3P4, Canada.
Oliver BucherDepartment of Epidemiology, CancerCare Manitoba, Winnipeg, MB R3E 0V9, Canada.
Zoann NugentDepartment of Biochemistry and Medical Genetics Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3E 3P4, Canada.
Ivan LandegoDepartment of Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3E 3P4, Canada.
Nicole BourrierPaul Albrechtsen Research Institute CancerCare Manitoba, Winnipeg, MB R3E 0V9, Canada.
Kelsey UminskiDepartment of Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3E 3P4, Canada.
Kevin BrownDepartment of Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3E 3P4, Canada.
Mandy SquiresPaul Albrechtsen Research Institute CancerCare Manitoba, Winnipeg, MB R3E 0V9, Canada.
Aaron J MarshallDepartment of Immunology, Max Rady College of Medicine, University of Manitoba, Rady Faculty of Health Sciences, Winnipeg, MB R3E 0T5, Canada.
Sachin KatyalPaul Albrechtsen Research Institute CancerCare Manitoba, Winnipeg, MB R3E 0V9, Canada.
Salah MahmudDepartment of Community Health Sciences, Max Rady College of Medicine Community Health Sciences, Winnipeg, MB R3E 0W2, Canada.
Kathleen DeckerDepartment of Epidemiology, CancerCare Manitoba, Winnipeg, MB R3E 0V9, Canada.ORCID 0000-0002-0044-7545
Marc GeirnaertDepartment of Pharmacy, CancerCare Manitoba, Winnipeg, MB R3E 0V9, Canada.
David E DaweDepartment of Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3E 3P4, Canada.ORCID 0000-0001-9762-3156
Spencer B GibsonDepartment of Biochemistry and Medical Genetics Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3E 3P4, Canada.ORCID 0000-0003-0119-732X
James B JohnstonDepartment of Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3E 3P4, Canada.ORCID 0000-0001-6614-083X
Versha BanerjiDepartment of Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3E 3P4, Canada.ORCID 0000-0002-7415-8818
CancerCare Manitoba · CAUniversity of Manitoba · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

FISH cytogenetics, TP53 sequencing, and IGHV mutational status are increasingly used as prognostic and predictive markers in chronic lymphocytic leukemia (CLL), particularly as components of the CLL International Prognostic Index (CLL-IPI) and in directing therapy with novel agents. However, testing outside of clinical trials is not routinely available in Canada. As a centralized CLL clinic at CancerCare Manitoba, we are the first Canadian province to evaluate clinical outcomes and survivorship over a long period of time, incorporating the impact of molecular testing and the CLL-IPI score. We performed a retrospective analysis on 1315 patients diagnosed between 1960 and 2018, followed over a 12-year period, where 411 patients had molecular testing and 233 patients had a known CLL-IPI score at the time of treatment. Overall, 40.3% (

Indexed as

Leukemia, Lymphocytic, Chronic, B-CellCanadaHumansMutationPrognosisRetrospective StudiesCLLIPImolecular testingoutcomesreal world evidencetreatments

Identifiers

PMID37504332
PMCPMC10378068
OpenAlexW4383375588

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.